Table 1 Demographic and clinical characteristics of the 144 patients with KPC Kp invasive infection included in the study
Variable | Number (%) of patients | p value | |
|---|---|---|---|
DC group (n = 48) | ST group (n = 96) | ||
Demographics and comorbidities | |||
Age (years), mean ± SD | 55.5 ± 15 | 61.3 ± 12 | 0.06 |
Males | 35 (72.9) | 58 (60.4) | 0.19 |
CHF | 18 (37.5) | 27 (28.1) | 0.34 |
COPD | 11 (22.9) | 12 (12.5) | 0.17 |
CRF | 8 (16.7) | 7 (7.3) | 0.15 |
Diabetes | 17 (35.4) | 31 (32.3) | 0.85 |
CLD | 10 (20.8) | 8 (8.3) | 0.06 |
Neoplasm | 2 (4.2) | 12 (12.5) | 0.21 |
Immunosuppressive status | 19 (39.6) | 26 (27.1) | 0.18 |
ICU stay before infection (days), median (IQR) | 11 (4–24) | 7 (1-22.5) | 0.08 |
Duration of MV before infection (days), median (IQR) | 6 (1.5-15.5) | 5 (1–14) | 0.57 |
Duration of vasopressors before infection (days), median (IQR) | 3 (1–10) | 1.5 (0–6) | 0.11 |
Presenting feature | |||
Medical admission | 25 (52.1) | 59 (61.5) | 0.37 |
Surgical admission | 18 (37.5) | 30 (31.3) | 0.28 |
Trauma admission | 5 (10.4) | 11 (11.5) | 0.92 |
SAPS II score, median (IQR) | 44 (36–56) | 46 (36–57) | 0.56 |
SOFA score at infection, median (IQR) | 9 (7–11) | 8 (6–10) | 0.33 |
Septic shock on occurrence of infection | 36 (75) | 43 (44.8) | <0.01 |
ARDS on occurrence of infection | 18 (37.5) | 23 (23.9) | 0.13 |
CRRT on occurrence of infection | 20 (41.7) | 26 (27.1) | 0.13 |
PCT on occurrence of infection (ng/ml), median (interval) | 6.1 (3.2–50.4) | 3.1 (0.8–5.9) | <0.01 |
Type of infection | |||
Pneumonia | 25 (52.1) | 49 (51) | 0.95 |
IAI | 9 (18.7) | 10 (10.4) | 0.19 |
SSTI | 1 (2.1) | 11 (11.5) | 0.06 |
UTI | 3 (6.2) | 9 (9.3) | 0.75 |
CVC BSI | 8 (16.7) | 10 (10.4) | 0.42 |
Primary BSI | 6 (12.5) | 10 (10.4) | 0.92 |
Secondary BSI | 23 (47.9) | 26 (27.1) | 0.02 |
Multiple site infection | 4 (8.2) | 3 (3.1) | 0.54 |
Therapeutic aspects | |||
IIAT | 13 (27.1) | 40 (41.7) | 0.16 |
Overall duration of treatment (days), median (interval) | 17 (11.5–25.5) | 11.5 (7.5–15.5) | <0.01 |
Clinical and microbiological outcome | |||
28-day mortality | 14 (29.2) | 46 (47.9) | 0.04 |
90-day mortality | 24 (50) | 58 (60.4) | 0.31 |
Clinical cure | 30 (62.5) | 47 (48.9) | 0.17 |
Microbiological eradicationa | 22 (50) | 31 (38.3) | 0.27 |
Duration of MV after infection (days), median (interval) | 14 (7.5–31) | 11.5 (7–19) | 0.16 |
Duration of vasopressors after infection (days), median (interval) | 10.5 (3.5–27.5) | 8 (4.5–12) | 0.19 |